Oxurion Updates Voting Rights Following Convertible Bond Conversion

Atlas Special Opportunities, LLC has converted four convertible bonds in Oxurion, resulting in a EUR 100,000 capital increase. This conversion is part of a larger EUR 20 million capital commitment aimed at advancing Oxurion’s therapeutic innovations for age-related vision preservation, addressing market opportunities valued between USD 3-6 billion.

Following the conversion, Oxurion's total shares increased to 3,638,344 from 3,192,223, enhancing voting rights. In compliance with Belgian regulations, these updates were necessary to ensure transparency regarding shareholding percentages.

Oxurion’s updated share capital now stands at EUR 85,406,161.32, with all shares carrying voting rights. The company highlights the ongoing potential for additional share conversions under the Atlas agreement. These developments position Oxurion for continued progress in ophthalmic therapeutics.